================================================================================
                    NPPA COMPLIANCE DOCUMENTATION
                    BIOPHARMA INDUSTRIES LIMITED
================================================================================

                    NATIONAL PHARMACEUTICAL PRICING AUTHORITY
                    (Ministry of Chemicals and Fertilizers, Government of India)

================================================================================

COMPANY REGISTRATION WITH NPPA

================================================================================

REGISTRATION DETAILS:

NPPA Registration Number:   NPPA/MH/2013/5678
Company Name:               BioPharma Industries Limited
CIN:                        U24230MH2012PLC234567
Registration Date:          June 15, 2013
Status:                     Active

Registered Office:          Plot No. 234-235, MIDC Industrial Area
                            Thane-Belapur Road, Rabale
                            Thane - 400701, Maharashtra

Authorized Signatory:       Mr. Rajesh Sharma (Chief Financial Officer)
                            Email: cfo@biopharma.com
                            Phone: +91-22-2568-XXXX

================================================================================

DRUG PRICE CONTROL ORDER (DPCO) 2013 COMPLIANCE

================================================================================

OVERVIEW:

The Company manufactures pharmaceutical formulations, of which certain products
fall under the National List of Essential Medicines (NLEM) and are subject to
price control under the Drug Prices Control Order (DPCO), 2013.

PRICE-CONTROLLED PRODUCTS:

Total Products Manufactured:           47
Products under Price Control (NLEM):   18
Non-price-controlled Products:         29

================================================================================

SCHEDULED FORMULATIONS (PRICE-CONTROLLED PRODUCTS)

================================================================================

The following products manufactured by the Company are included in the First
Schedule of DPCO, 2013 (National List of Essential Medicines) and are subject
to ceiling price:

S.No  Product Name                     Ceiling Price    MRP      Pack Size
                                       (per unit)       (per unit)
--------------------------------------------------------------------------------
1.    Metformin Hydrochloride          Rs. 1.85         Rs. 1.75  Per tablet
      500mg Tablet

2.    Metformin Hydrochloride          Rs. 2.12         Rs. 2.00  Per tablet
      850mg Tablet

3.    Metformin Hydrochloride          Rs. 2.65         Rs. 2.50  Per tablet
      1000mg Tablet

4.    Amlodipine Besylate              Rs. 1.24         Rs. 1.15  Per tablet
      5mg Tablet

5.    Amlodipine Besylate              Rs. 1.89         Rs. 1.75  Per tablet
      10mg Tablet

6.    Atenolol 50mg Tablet             Rs. 0.82         Rs. 0.75  Per tablet

7.    Atenolol 100mg Tablet            Rs. 1.38         Rs. 1.25  Per tablet

8.    Losartan Potassium               Rs. 3.42         Rs. 3.25  Per tablet
      50mg Tablet

9.    Omeprazole 20mg Capsule          Rs. 2.89         Rs. 2.75  Per capsule

10.   Pantoprazole 40mg Tablet         Rs. 3.45         Rs. 3.25  Per tablet

11.   Ranitidine 150mg Tablet          Rs. 1.12         Rs. 1.00  Per tablet

12.   Paracetamol 500mg Tablet         Rs. 0.85         Rs. 0.75  Per tablet

13.   Ibuprofen 400mg Tablet           Rs. 1.45         Rs. 1.35  Per tablet

14.   Amoxicillin 250mg Capsule        Rs. 3.28         Rs. 3.10  Per capsule

15.   Amoxicillin 500mg Capsule        Rs. 5.82         Rs. 5.50  Per capsule

16.   Ciprofloxacin 500mg Tablet       Rs. 4.67         Rs. 4.50  Per tablet

17.   Albendazole 400mg Tablet         Rs. 3.12         Rs. 2.95  Per tablet

18.   Ferrous Sulphate +               Rs. 1.24         Rs. 1.15  Per tablet
      Folic Acid Tablet

--------------------------------------------------------------------------------

PRICING FORMULA (As per DPCO, 2013):

Ceiling Price = (Sum of prices of all brands with >1% market share) /
                (Number of such brands)

Ceiling Price is calculated by NPPA based on market data and notified in
official gazette.

RETAIL PRICE FORMULA:

Maximum Retail Price = Ceiling Price + Retailer Margin (16%) + GST

--------------------------------------------------------------------------------

ANNUAL PRICE REVISION:

Prices of scheduled formulations can be increased annually only to the extent
of change in Wholesale Price Index (WPI).

WPI-based Price Increase History:

Year        WPI Increase    Price Revision Applied
-----------------------------------------------
2020-21     1.32%           Yes - March 2021
2021-22     3.45%           Yes - April 2022
2022-23     5.67%           Yes - April 2023
2023-24     4.12%           Yes - April 2024
2024-25     3.85%           Yes - April 2025

================================================================================

NON-SCHEDULED FORMULATIONS

================================================================================

For non-price-controlled products, the Company is required to comply with
Paragraph 20 of DPCO, 2013:

PRICE INCREASE CAP:

- Maximum price increase allowed: 10% in any 12-month period
- Calculated on manufacturer's MRP (excluding GST)

The Company's non-scheduled products and pricing:

S.No  Product Name                     MRP          Last Price    Increase
                                       (Current)    Revision      (%)
--------------------------------------------------------------------------------
1.    Atorvastatin 10mg Tablet         Rs. 8.50     Apr 2024      8.5%
2.    Atorvastatin 20mg Tablet         Rs. 12.00    Apr 2024      8.5%
3.    Rosuvastatin 10mg Tablet         Rs. 15.00    Apr 2024      9.0%
4.    Azithromycin 250mg Tablet        Rs. 28.00    Jul 2025      7.5%
5.    Azithromycin 500mg Tablet        Rs. 45.00    Jul 2025      7.5%
6.    Cefixime 200mg Tablet            Rs. 38.00    Aug 2025      8.0%
7.    Cefpodoxime 200mg Tablet         Rs. 52.00    Apr 2024      9.5%
8.    Pantoprazole 40mg +
      Domperidone 30mg SR Cap          Rs. 12.50    Sep 2025      N/A (New)
...   (Complete list maintained)

All price increases are within the 10% annual cap as per DPCO, 2013.

================================================================================

QUARTERLY RETURNS FILED WITH NPPA

================================================================================

As per Para 24 of DPCO, 2013, the Company files quarterly returns with NPPA
providing information on:

1. Production quantity of scheduled formulations
2. Stock position
3. Sales quantity and value
4. Interstate stock transfers

RETURN FILING STATUS:

Quarter              Filing Due Date    Filed On       Status
--------------------------------------------------------------------------------
Q1 FY 2024-25       July 15, 2024      July 12, 2024   Timely
Q2 FY 2024-25       Oct 15, 2024       Oct 10, 2024    Timely
Q3 FY 2024-25       Jan 15, 2025       Jan 12, 2025    Timely
Q4 FY 2024-25       Apr 15, 2025       Apr 14, 2025    Timely
Q1 FY 2025-26       July 15, 2025      July 10, 2025   Timely
Q2 FY 2025-26       Oct 15, 2025       Oct 12, 2025    Timely

All returns filed through NPPA's online Integrated Pharmaceutical Database
Management System (IPDMS).

================================================================================

ANNUAL RETURNS (FORM V)

================================================================================

As per Para 25 of DPCO, 2013, the Company files Annual Return (Form V)
providing audited information on:

1. Total turnover
2. Category-wise sales (scheduled vs non-scheduled)
3. Product-wise production, sales, and closing stock
4. Profit margins

FORM V FILING STATUS:

Financial Year       Filing Due Date    Filed On       Status
--------------------------------------------------------------------------------
FY 2022-23          May 31, 2023       May 28, 2023   Timely
FY 2023-24          May 31, 2024       May 25, 2024   Timely
FY 2024-25          May 31, 2025       May 29, 2025   Timely

================================================================================

TRADE MARGIN RATIONALIZATION

================================================================================

As per NPPA's Trade Margin Rationalization orders, the following products
manufactured by the Company have been brought under margin capping:

PRODUCTS UNDER TRADE MARGIN RATIONALIZATION:

These are non-scheduled medicines used in treatment of cancer, diabetes,
cardiovascular diseases, etc., where MRP to retailer purchase price ratio
exceeds 35%.

Currently, the Company does not manufacture any products falling under
Trade Margin Rationalization orders.

================================================================================

OVERCHARGING CASES AND COMPLIANCE

================================================================================

OVERCHARGING STATUS:

The Company has NO overcharging cases pending with NPPA or DPCO enforcement
authorities.

COMPLIANCE CERTIFICATE:

This is to certify that BioPharma Industries Limited:

1. Has not charged prices exceeding the ceiling price for any scheduled
   formulation

2. Has not increased prices of non-scheduled formulations by more than 10%
   in any 12-month period

3. Has filed all quarterly and annual returns with NPPA within due dates

4. Has maintained proper records of production, sales, and pricing as
   required under DPCO, 2013

5. Has not received any show cause notice or penalty order from NPPA for
   overcharging

VERIFICATION:

Period Covered:     April 1, 2020 to September 30, 2025
Verified By:        M/s. DEF & Co., Chartered Accountants (Statutory Auditors)
Date of Certificate: October 10, 2025

                                             Sd/-
                                             Mr. Rajesh Sharma
                                             Chief Financial Officer

================================================================================

PRICE NOTIFICATIONS AND COMPLIANCE

================================================================================

The Company monitors the following NPPA notifications for price compliance:

1. Ceiling Price Notifications (for scheduled formulations)
2. WPI-based annual price revision notifications
3. Trade margin rationalization orders
4. Para 19 price fixation orders
5. New additions to NLEM

RECENT PRICE NOTIFICATIONS AFFECTING COMPANY:

Notification No.           Date           Impact on Company
--------------------------------------------------------------------------------
S.O. 2345(E)              Apr 1, 2025     WPI increase 3.85% - Applied
S.O. 1234(E)              Jan 15, 2025    New ceiling for Omeprazole - Complied
S.O. 5678(E)              Oct 10, 2024    New ceiling for Losartan - Complied

================================================================================

PRICE DISPLAY AND LABELING COMPLIANCE

================================================================================

As per DPCO, 2013 and Legal Metrology Act:

1. Maximum Retail Price (MRP) is printed on all product labels
2. MRP is inclusive of all taxes
3. Unit sale price is displayed for scheduled formulations
4. "Price to Retailer" is printed for scheduled formulations
5. Generic name is printed in larger font than brand name

COMPLIANCE STATUS: Fully Compliant

================================================================================

CONTACT INFORMATION FOR NPPA MATTERS

================================================================================

Company Representative:

Name:               Mr. Rajesh Sharma
Designation:        Chief Financial Officer
Email:              cfo@biopharma.com
Phone:              +91-22-2568-XXXX
Mobile:             +91-98XXX-XXXXX

NPPA Correspondence Address:

National Pharmaceutical Pricing Authority
3rd & 5th Floor, YMCA Cultural Centre Building
1, Jai Singh Road, New Delhi - 110001
Phone: 011-2336-1897
Email: nppa-dop@gov.in
Website: www.nppaindia.nic.in

================================================================================

UNDERTAKING

================================================================================

We, BioPharma Industries Limited, hereby undertake that:

1. We shall comply with all provisions of the Drug Prices Control Order, 2013
   and amendments thereto.

2. We shall not charge prices exceeding the ceiling price for scheduled
   formulations.

3. We shall not increase prices of non-scheduled formulations by more than
   10% in any 12-month period without prior approval.

4. We shall file all returns and reports as required under DPCO, 2013.

5. We shall maintain records of production, sales, and pricing for a period
   of 5 years.

6. We shall cooperate with NPPA authorities for any inspection or verification.

7. In case of any overcharging, we shall deposit the overcharged amount along
   with interest and penalty as determined by NPPA.

                                             Sd/-
                                             Dr. Ramesh Narayan Kulkarni
                                             Managing Director

Date: November 1, 2025
Place: Thane, Maharashtra

================================================================================
                    END OF NPPA COMPLIANCE DOCUMENTATION
================================================================================
